Merck & Company Inc (MRK)vsX4 Pharmaceuticals Inc (XFOR)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
XFOR
X4 Pharmaceuticals Inc
$3.50
+2.94%
HEALTHCARE · Cap: $400.55M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 419973% more annual revenue ($66.57B vs $15.85M). MRK leads profitability with a 4.8% profit margin vs 0.0%. XFOR trades at a lower P/E of 2.8x. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
XFOR
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+70.0%
Fair Value
$11.44
Current Price
$3.50
$7.94 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Attractively priced relative to earnings
Revenue surging 346.3% year-over-year
Reasonable price relative to book value
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -58.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : XFOR
The strongest argument for XFOR centers on P/E Ratio, Revenue Growth, Price/Book. Revenue growth of 346.3% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : XFOR
The primary concerns for XFOR are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while XFOR is a hypergrowth play — different risk/reward profiles.
XFOR carries more volatility with a beta of 0.40 — expect wider price swings.
XFOR is growing revenue faster at 346.3% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 35/100). XFOR offers better value entry with a 70.0% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →X4 Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back diseases. The company is headquartered in Boston, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?